Gary Gordon
Direttore/Membro del Consiglio presso BioSight Ltd.
Profilo
Gary Gordon is currently a Director at BioSight Ltd.
and also holds Director positions at PhotonPharma, Inc. and Israel Biotech Fund.
Previously, he held Director positions at G.D.
Searle Co. and Abbott Laboratories, as well as Vice President positions at AbbVie, Inc. and OVATION Pharmaceuticals, Inc. He also served as Assistant Professor at The Johns Hopkins University School of Medicine and Chief Medical Officer at Old Ayala, Inc. Gordon received his undergraduate degrees from Stony Brook University and The State University of New York, and his doctorate from The Johns Hopkins University School of Medicine.
Posizioni attive di Gary Gordon
Società | Posizione | Inizio |
---|---|---|
BioSight Ltd.
BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Direttore/Membro del Consiglio | 18/05/2020 |
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Direttore/Membro del Consiglio | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consulente / Consigliere | - |
Precedenti posizioni note di Gary Gordon
Società | Posizione | Fine |
---|---|---|
ABBVIE INC. | Corporate Officer/Principal | 01/04/2018 |
G.D. Searle Co. | Investitore di Private Equity | - |
The Johns Hopkins University School of Medicine | Corporate Officer/Principal | - |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Direttore Tecnico/Scientifico/R&S | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Formazione di Gary Gordon
Stony Brook University | Undergraduate Degree |
The State University of New York | Undergraduate Degree |
The Johns Hopkins University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
ABBVIE INC. | Health Technology |
Aziende private | 6 |
---|---|
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
BioSight Ltd.
BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Commercial Services |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Old Ayala, Inc.
Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
G.D. Searle Co. | Commercial Services |
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Health Technology |
- Borsa valori
- Insiders
- Gary Gordon